Human T-cell leukemia virus types I (HTLV-I) and II (HTLV-II) are human retroviruses which normally infect T-lymphoid cells. HTLV-I infection is associated with adult T-cell leukemia-lymphoma, and HTLV-II is associated with an indolent form of hairy-cell leukemia. To identify potential transcriptional regulatory elements of these two related human retroviruses, we performed DNase I footprinting of both the HTLV-I and HTLV-II long terminal repeats (LTRs) by using extracts prepared from uninfected T cells, HTLV-I and HTLV-II transformed T cells, and HeLa cells. Five regions of the HTLV-I LTR and three regions of the HTLV-II LTR showed protection by DNase I footprinting. All three of the 21-base-pair repeats previously shown to be important in HTLV transcriptional regulation were protected in the HTLV-I LTR, whereas only one of these repeats was protected in the HTLV-II LTR. Several regions exhibited altered protection in extracts prepared from lymphoid cells as compared with HeLa cells, but there were minimal differences in the protection patterns between HTLV-infected and uninfected lymphoid extracts. A number of HTLV-I and HTLV-II LTR fragments which contained regions showing protection in DNase I footprinting were able to function as inducible enhancer elements in transient CAT gene expression assays in the presence of the HTLV-II tat protein. The alterations in the pattern of the cellular proteins which bind to the HTLV-I and HTLV-II LTRs may in part be responsible for differences in the transcriptional regulation of these two related viruses.
The human T-cell leukemia virus types I (HTLV-I) and II (HTLV-II) are retroviruses which have been associated with human T-cell leukemias (18, 33, 35, 36, 53, 59, 60) . HTLV-I is the etiologic agent of a highly aggressive leukemia-lymphoma (33, 35, 53) , and HTLV-II has been associated with two cases of atypical hairy-cell leukemia (36, 59, 60) . Both viruses have been shown to transform human T cells in vitro (6, 46, 54, 77) ; however, the reasons for the differences in the clinical diseases associated with these viruses are unknown.
The genetic organization of these two human retroviruses is similar (62, 65) . In addition to the three genes normally found in retroviruses (gag, pol, and env), they contain at the 3' portion of the genome additional open reading frames that encode three proteins (29, 37, 43, 69) . One of these proteins, tat, is a nuclear protein (24, 68) important in both viral replication (7) and transcriptional activation (4, 14, 15, 21, (70) (71) (72) . The HTLV-I and HTLV-IT tat proteins differ in their molecular masses (43, 69) and transcriptional activating properties (64, 72) . The molecular masses of the HTLV-I and HTLV-II tat proteins are 40 and 37 kilodaltons, respectively (43, 69) . The HTLV-II tat protein is capable of transcriptional activation of both the HTLV-I and HTLV-II long terminal repeats (LTRs), whereas the HTLV-I tat protein is capable of activating only the HTLV-I LTR (64, 72) . Differences in both the structure of the tat proteins and the regulatory sequences present in each LTR may be responsible for this altered transcriptional activation (4, 14, 15, 58, 63, 64, 71, 72) .
Mutagenesis experiments indicate that several regions in the U3 region of the HTLV LTR are involved in transcriptional activation (3, 16, 48, 49, 56, 57, 63, 66) . Both the HTLV-I and HTLV-II LTRs contain three 21-base-pair (bp) * Corresponding author.
imperfect direct repeated sequences (62, 65) which are important in basal and tat-induced transcriptional regulation (3, 16, 48, 49, 56, 57, 63, 66) . Two of these 21-bp repeats are contained in 51-bp imperfect repeated units in the HTLV-I LTR (62, 65) . Several studies have indicated that a single 51-or 21 -bp repeat was sufficient to give low levels of tatinduced transactivation either when present in the HTLV LTR (3, 16, 49, 56, 63) or when oligonucleotides complementary to the 21-bp repeat were inserted into an enhancerless early-region similar virus 40 (SV40) promoter (66) . However, the level of trans-activation was higher when a 21-bp repeat was present in the HTLV LTR compared with heterologous promoters (3, 56, 66) . Multiple copies of the 21-bp repeats also increased the level of trans-activation when present both in the HTLV LTR and in heterologous promoters (3, 56, 66) . These results suggest that the 21-bp repeats act as inducible enhancer elements in the presence of the tat protein and that both the number of these repeats and the surrounding LTR sequences influence the level of transactivation. Other studies have shown that regions other than the 21-bp repeats may also be important in gene expression of the HTLV-I LTR. These include a sequence important in basal transcriptional regulation located between -306 and -242 (57), a sequence important in tat-induced transcriptional regulation located between -160 and -117 (3, 49) , and sequences in the R and U5 regions of the LTR which may be important in the efficiency of mRNA utilization or stability (48, 56, 57 regulation. We began an investigation of the cellular DNAbinding proteins involved in the transcriptional regulation of the HTLV-I and HTLV-II LTRs. DNase I footprinting (17) of both the HTLV-I and HTLV-II LTRs with extracts prepared from HeLa cells, uninfected T lymphoid cells, and HTLV-I-and HTLV-II-transformed lymphoid cells indicated that multiple regions of both LTRs serve as binding sites for cellular proteins. Several HTLV-I and HTLV-II LTR fragments which had been shown to contain protected regions by DNase I footprinting were fused to plasmids containing the CAT gene and found to be inducible by the HTLV-II tat protein in transient-expression assays. These results demonstrate that the alterations in the pattern of cellular proteins which bind to the HTLV-I and HTLV-II LTRs may in part be responsible for differences in the transcriptional regulation of these two related viruses.
MATERIALS AND METHODS DNA constructions and fragments used in DNase I footprinting. To generate plasmids in which probes for DNase I footprinting could be isolated, a 342-bp HhaI-SmaI fragment (+22 to -322) from the HTLV-I LTR (62) and a 345-bp BamHI-AvaI fragment (+52 to -293) from the HTLV-II LTR (66) were cloned into the SmaI site and the SmaIBamHI sites of pUC19, respectively.
To footprint the noncoding strand of the HTLV-I LTR a 576-bp EcoRI-PvuII fragment labeled at the EcoRI site was isolated from the HhaI-SmaI-containing HTLV-I pUC19 construct, whereas a 455-bp BamHI-PvuII fragment from this clone labeled at the BamHI site was used to footprint the coding strand. To footprint the noncoding strand of the HTLV-II LTR, a 451-bp or a 358-bp BamHI-PvuII fragment labeled at the BamHI site was isolated from the AvaI-AluI or the AvaI-BamHI HTLV-II construct, respectively, whereas a 572-bp EcoRI-PvuII fragment from the latter clone labeled at the EcoRI site was used to footprint the coding strand. All probes used for DNase I footprinting were end labeled by using _y32p with T4 kinase, and the fragments were gel isolated and electroeluted before being used in DNase I footprinting assays.
The HTLV-I fragments used for construction of HTLV-I LTR-CAT gene fusions included fragments restricted at Hinfl-SmaI (-33 to -322), Hinfl-AluI (-33 to -167), MboIISmaI (-169 to -322), and Hinfl-AhaII (-33 to -244). The HTLV-II fragments used for construction of HTLV-II LTR-CAT gene fusions were HinfI-Hinfl (-27 to -271), AluI-Hinfl (-144 to -271), and Hinfl-AluI (-27 to -144). Each fragment was treated with Klenow fragment, gel isolated, and ligated into pUC19 which had been cut with XbaI and end filled with Klenow fragment. These clones were then cut at the BamHISall sites in the pUC19 polylinker and ligated into BglII-SalI pAlO CAT, which is an enhancerless SV40 CAT fusion (40) . Clones which contained inserts in both orientations were selected for use in transfection assays.
Cell lines and preparation of cellular extracts. HeLa spinner cells were maintained in suspension culture in minimal essential medium with 5% newborn calf serum. H9 (an uninfected T-cell lymphoid cell line) (19) , Mo (an HTLV-II infected T-cell lymphoid cell line) (60) , and SLB (an HTLV-I infected T-cell lymphoid cell line) (38) For all extracts, a minimum of 7 ml (packed cell volume) was used. Nuclear extracts were prepared as described previously (12) (20, 76) . G+A and C+T MaxamGilbert sequencing reactions were performed for each probe. All gels were then subjected to autoradiography.
Transfection conditions. For the transfections of the HTLV-I LTR-CAT and HTLV-II LTR-CAT constructs, HeLa cell plates were split on the day prior to transfection so that cells were 50 to 75% confluent at the time of transfection. The constructs (10 ,ug each) in either the presence of an expression plasmid containing the tat-II gene (4) or a betaglobin control plasmid (27) were transfected by using calcium phosphate with glycerol shock at 4 h as described previously (76) . Transfected cells were harvested at 48 h and used for assays of chloramphenicol acetyltransferase (CAT) activity as described previously (26, 27) . Following autoradiography of each CAT assay, both the unacetylated and acetylated chloramphenicol were quantitated by scintillation counting.
RESULTS
DNase I footprinting of the HTLV-I LTR. DNase I footprinting of both the coding and noncoding strands of the HTLV-I LTR was performed to identify cellular DNAbinding proteins. Owing to the large distances between several of these binding sites and the difficulty in visualizing DNase I-protected regions near the top of the gels, some sites are visualized only on one of the two DNA strands. Partially purified cellular extracts prepared from HeLa, H9 (T-cell lymphoid cell line) (19) , Mo (HTLV-II transformed T-cell line) (60) , and SLB (HTLV-I transformed T-cell line) (38) were used in these studies.
DNase I footprinting of the HTLV-I LTR revealed five protected regions ( Fig. 1A and B). Sites 1, 2, 3, and 4 are seen on the noncoding strand (Fig. 1A) , whereas sites 4 and 5 are seen on the coding strand (Fig. 1B) . Relative to the transcriptional start site, site 1 extends from -38 to -74, site 2 extends from -82 to -97, site 3 extends from -110 to -151, site 4 extends from -192 to -247, and site 5 extends from -258 to -273. On the noncoding strand (Fig. 1A ) partial protection was seen over site 1, whereas sites 2, 3, and 4 gave relatively complete protection. On the coding strand there was extension of protection over site 4 in lymphoid extracts (Fig. 1B , lanes 1 to 5) as compared with HeLa cell extracts (Fig. 1B, lanes 6 and 7) , such that the 21-bp repeat farthest from the transcriptional start site was completely protected only in lymphoid extracts. There was partial protection on the coding strand over site 5 with all cell lines tested (Fig. 1B) .
A summary of the sequences protected in the HTLV-I (Fig. 3 ) Sites 1 and 2 are seen on the noncoding strand (Fig. 3A) , whereas sites 1, 2, and 3 are seen on the coding strand (Fig. 3B) . Relative to the transcriptional start site, site 1 extends from -35 to -51, site extends 2 from -180 to -221, and site 3 extends from -247 to -261.
On the noncoding strand, there was protection over sites 1 and 2. Extracts prepared from the HTLV-II-infected cell line (Mo) gave extended protection over site 1 as compared with extracts prepared from the other cell lines (Fig. 3A sion of protection over a core viral enhancer sequence in extracts prepared from lymphoid cell lines (Fig. 3B , lanes 1 to 6) as compared with HeLa cell extracts (Fig. 3B, lanes 7 and   8 ). This extended protection over the enhancer sequence in site 2 with lymphoid extracts (SLB, H9, and Mo) was also shown by using a shorter HTLV-II fragment (AvaI-AluI), which contains both binding sites 2 and 3 (Fig. 3C ). There was also protection over site 3 with these extracts (Fig. 3C) .
A summary of the sequences protected in the HTLV-II LTR is shown in Fig. 4 . An examination of these sequences reveals that site 1 contains the DNA sequence encoding the polyadenylation recognition sequence which is located 10 (Fig. 2) .
Transcriptional regulation of the HTLV-I and HTLV-1I
LTRs. To determine the significance of each of the protected regions in the HTLV-I and HTLV-II LTRs in the transcriptional regulation of the viral LTR, a series of fragments which served as binding domains for cellular proteins were inserted into enhancerless SV40 plasmid pAlO CAT (40 tions gave lower levels of tat-II induced CAT activity than did the fragment which contained all five binding domains (Fig. SA, lanes 5 to 16) . The pAlO CAT vector was not induced by the tat-II protein (data not shown). However, all fragments remained inducible by the tat-II protein.
For the HTLV-II LTR CAT constructs, a fragment containing all three binding domains (-27 to -277) gave strong induction in response to tat-II (Fig. SB, lanes 1 to 4) . The fragment which contained only binding sites 2 and 3 (-144 to -271) gave full induction in the sense orientation, but decreased induction in the antisense orientation (Fig. SB,  lanes 5 to 8) . The plasmid containing site 1 alone gave no induction in the sense orientation (Fig. SB, lanes 9 and 10) or the antisense orientation (data not shown).
The induced levels of CAT activity in the presence of the tat-II protein for each of the HTLV-I (Fig. 6A ) and the HTLV-II (Fig. 6B) (Fig. 6B) . When site 1 was deleted, there was a 9% CAT conversion in the sense orientation, but a decrease in induction in the antisense orientation. When binding sites 2 and 3 were deleted, the percent CAT conversion in response to tat-II did not differ from basal levels. Further studies are required to determine the relative effects of sites 2 and 3 on transcriptional induction of the HTLV-II LTR. Several previous mutagenesis studies of the HTLVV-LTR indicated that multiple regions of the LTR were required transcriptional regulation (3, 16, 48, 49, 56, 57, 63, 66 (3, 16, 49, 56, 66) . Data on the number of these 21-hp repeats critical for trans-activation differed (3, 16, 49, 56, 66) . However, it is clear that the level of tat-induced induction is low when only one 21-bp repeat is present and that this induction increases markedly when several of these repeats are present (3, 16, 49, 56, 66) . In addition, when oligonucleotides complementary to the 21-bp repeats were tested with heterologous promoters, the level of trans-activation appeared lower than when these elements were present in the viral LTR (3, 66) . Thus, sequences other than the 21-bp repeats are probably likely involved in transcriptional regulation of the HTLVI LTR, and the spacing between these sequences may be important (3, 48, 49, 56, 
57).
Other studies on the HTLV-I LTR have demonstrated the importance of a region between -242 and -306 that is important in basal transcription (57) , a region between -117 and -160 that is important in tat-induced activation (3, 49) , and a region between +315 and -159 that is important in gene expression, perhaps by increasing mRNA stability or utilization (48, 56, 57) . Our studies do not characterize the relative effects of these other HTLV regulatory regions with respect to those of the 21-bp repeats. Oligonucleotidedirected mutagenesis of the HTLV LTR will be required to address this point.
The DNase I footprinting results presented here are consistent with previous mutagenesis results indicating that multiple regions of the HTLV-I LTR are important in its transcriptional regulation. Five binding domains were noted in the HTLV-I LTR, but DNase I footprinting of even longer LTR fragments is required to definitively show the total number of binding sites present. Site 1 contains the DNA sequence encoding the polyadenylation recognition site and a region near position -55 previously suggested tobe an important region in HTLV-I transcriptional regulation (57) . Site 2 contains the first 21-bp repeat. Site 3 contains two direct repeats of a sequence, GAAGCCCACC, which has been shown to be located in a region important in tatinduced trans-activation (3, 49) . Within this larger repeated sequence, a smaller sequence, CA(A/T)CC, is repeated four times in site 3. Site 4 contains a 58-bp DNase I protected region which is flanked by two 21-bp repeats. Site 5 contains a sequence, TAAAAGGTCAG, which may be important in regulating basal levels of transcription (57) .
A detailed mutational analysis of the HTLV-II LTR has not been reported. However, oligonucleotides complementary to the HTLV-II 21-bp repeats have been shown to function as tat-inducible enhancer elements (66) . DNase I footprinting of the HTLV-II LTR reveals three regions of DNase I protection. Site 1 includes the DNA sequence encoding the polyadenylation recognition sequence and corresponds to a similar protected region seen in the HTLV-I LTR (site 1). Site 2 contains the 21-bp repeat farthest from the transcriptional start site and a viral enhancer core sequence, TAGGAACTGAA, which is not present in the HTLV-I LTR. This enhancer sequence has been demonstrated for a number of other promoters including those of a number of viruses (adenovirus, polyomavirus, SV40, Moloney leukemia virus, Friend leukemia virus, avian sarcoma virus, and mouse mammary tumor virus [10, 13, 25, [30] [31] [32] ) and the beta interferon gene (25) . DNase I protection over site 2 differs in extracts prepared from lymphoid cells compared with HeLa cells. Similar alterations in binding over enhancer sequences by using lymphoid cell rather than HeLa cell extracts have been demonstrated for SV40 (11) and the human immunodeficiency virus (76) . This altered binding may affect the regulation of certain genes in lymphoid cells (2, 22, 28 Multiple sequences and cellular proteins are probably required for transcriptional regulation of HTLV-I and HTLV-II. At present it is not clear how many cellular proteins bind to each site, but it appears that some sites may bind multiple cellular proteins. It is likely that the interaction of proteins binding to these transcriptional regulatory elements is important in both basal and tat-induced transcriptional regulation. However, it is unlikely that the tat protein itself directly binds to the viral LTR or results in major alterations in DNase I footprinting of the viral LTR, since extracts prepared from HTLV-infected lymphoid cells do not differ markedly from uninfected lymphoid cell extracts. More likely, the tat proteins which can also stimulate a variety of cellular and viral genes (5, 9, 45) act indirectly in a manner similar to the adenovirus ElA protein (34, 39, 42, 67, 78) . Differences in transcriptional regulatory sequences, the number and type of cellular DNA-binding proteins, and the specificity of the tat proteins may all be responsible for the differences observed in the genetic regulation between HTLV-I and HTLV-II.
